Dakers J M, Boulton D W, Fawcett J P
School of Pharmacy, University of Otago, Dunedin, New Zealand.
J Chromatogr B Biomed Sci Appl. 1997 Dec 19;704(1-2):215-20. doi: 10.1016/s0378-4347(97)00422-2.
The four stereoisomers of the combined alpha- and beta-adrenoceptor antagonist labetalol were separated and quantified at therapeutic concentrations by normal-phase high-pressure liquid chromatography using a chiral stationary phase and fluorescence detection. Drug in plasma or urine was recovered by solid-phase extraction with 83+/-5% efficiency. Limits of detection from biological samples (3 ml) were between 1.5-1.8 ng ml(-1). Intra-day and inter-day variation at 25 ng ml(-1) were < or = 2.7% and < or = 5.80% respectively for all stereoisomers. The assay was applied to an examination of the disposition of labetalol stereoisomers after a single oral dose of racemate to a human volunteer. Labetalol appears to undergo enantioselective metabolism leading to relatively low plasma concentrations of the pharmacologically active enantiomers.
采用手性固定相和荧光检测的正相高效液相色谱法,对α、β肾上腺素受体联合拮抗剂拉贝洛尔的四种立体异构体在治疗浓度下进行了分离和定量分析。血浆或尿液中的药物通过固相萃取回收,回收率为83±5%。生物样品(3 ml)的检测限在1.5 - 1.8 ng ml⁻¹之间。所有立体异构体在25 ng ml⁻¹时的日内和日间变异分别≤2.7%和≤5.80%。该检测方法用于检测一名人类志愿者单次口服消旋体后拉贝洛尔立体异构体的处置情况。拉贝洛尔似乎经历对映体选择性代谢,导致药理活性对映体的血浆浓度相对较低。